<DOC>
	<DOCNO>NCT02092207</DOCNO>
	<brief_summary>This control study determine effectiveness safety KL7016 treatment adult patient dry eye syndrome ( DES ) .</brief_summary>
	<brief_title>Phase 2 Study Evaluation Safety Efficacy Orally Administered KL7016 Patients With Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Corneal stain score ≥5 either eye National Eye Institute/Industry Workshop guideline Schirmer test score ( without anesthesia ) &lt; 7 mm/5 min either eye Willing use topical ocular treatment , REFRESH TEARS® duration trial Intraocular surgery within 3months Persistent intraocular inflammation infection Corneal transplantation neurotrophic keratitis StevensJohnson Syndrome Ocular herpes simplex virus infection Concomitant use contact lenses use within 3months Silicone lacrimal punctal occlusion cauterization punctum within 3months Vision correction surgery without DES within 12months Unstable use methotrexate Diseasemodifying drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>